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1. Introduction
  It is now 27 years after the first published report on HIV 
and the global epidemic continues unabated, with estimates 
of over 33 million people currently infected, Worldwide[1].
Tropical and developing countries like ours are worse hit by 
the overwhelming consequences of HIV/AIDS pandemonium. 
  Development of targeted therapies aimed at perturbing 
the HIV life cycle can be achieved only with a detailed 
comprehension of the dynamics of virus-host interactions 
within the cell. One of such critical virus-host interaction 
is the recently elucidated interplay between the viral 
Vif (Virion infectivity factor) protein and innate immune 
defense molecules APOBEC3G. APOBEC3G potently 
suppresses HIV replication but, Vif can alleviate this 
inhibition, rescuing viral infectivity[1].
  Vif acts by binding to APOBEC3G, introducing its protein 
degradation within infected cells and reducing its levels in 
progeny virions. Interventions that interfere with the 
Vif-APOBEC3G interaction, raise intracellular or virion 
associated levels of APOBEC3G or reduce the levels of Vif[2]. 
It follows logically, that higher levels of APOBEC3G in an 
individual shall possibly immunize the person against HIV/
AIDS. Transmission of HIV to a new host could normally 
occur via any means that admits or allows blood or some 
blood products into the vasculature of the new host from 
an already infected individual. The entry of blood cells 
is in most cases dependent on chance and volume thus 
whole blood transfusion remains the most potent means of 
HIV transmission. HAART reduces the risk of HIV sexual 
transmission; for individuals with chronically suppressed 
viral loads, the transmission risk may be negligible in the 
absence of sexually transmitted infections (STIs). It has 
been justified that HIV positive individuals with up to 800 
CD4 do not transmit HIV to their sexual partners[3].
  In Nigeria 80% of HIV infections are transmitted by 
heterosexual sex. Factors contributing to this include a 
lack of information about sexual health and HIV, low levels 
of condom use and high levels of STIs such as chlamydia 
and gonorrhea, which make it easier for the virus to be 
transmitted. Blood transfusions are responsible for 10% of 
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all HIV infections[4].
  There is a high demand for blood because of road traffic 
accidents, blood loss from surgery and childbirth, and 
anaemia from malaria. As there is no effective coordinated 
national blood supply system, blood is not routinely tested 
for HIV, and a study revealed that 4% of blood donors 
in Lagos were HIV positive. The remaining 10% of HIV 
infections are acquired through other routes such as mother-
to-child transmission, homosexual sex and injectable drug 
abuse. The rate of mother-to-child transmission in Nigeria 
has gone up in recent years as the number of HIV positive 
women has increased[5]. 
  A recent study has shown that Hepatitis B and C co-
infection with HIV might also be a major factor of virulence 
particularly, among Nigerian inmates in Nasarawa State, 
Northern Nigeria[6]. 
  Homosexuality other than sharing of injections drugs may 
be a realistic source of spread, they insinuated. The global 
prevalence of HIV-1 has stabilized at 0.8%, with 33 million 
people living with HIV/AIDS, 2.7 million new infections, and 
2.0 million AIDS deaths in 2007[7].
  Heterosexual spread in the general population is the main 
mode of transmission in sub-Saharan Africa, which remains 
the most heavily affected region, with 67% of the global 
burden. Male-male sex, injection drug use, and sex work 
are the predominant risk factors in most other regions.
  Infection rates are declining in some regions, including 
some of the most heavily affected countries in Africa, but 
climbing elsewhere such as in eastern Europe and central 
Asia[7]. 
  Recent HIV epidemiologic research findings include 
new insights into the role of HIV viral load, co-infection 
with sexually transmitted infections, male circumcision, 
antiretroviral treatment, serosorting, and superinfection in 
HIV transmission and prevention[7]. 
  These foregoing justifies the pressing need for an urgent 
means of curbing spread through a clearer understanding 
of the interplay of the natural defense mechanism and 
possibly developing drugs that act like these natural defense 
mechanisms. 
 
2. Cases report 1
  Our first case report involves a middle age married woman, 
a mother of two, a petty-trader and part-time Church 
Orderly. The husband is unemployed. She presented at our 
clinic with recurrent fever, anorexia and twitches-kind of 
skin irritations. She also had secondary infertility of about 8 
years standing. She lives with her family. 
  Blood sample was collected for WIDAL, MP, HB, TPHA, 
HBSAG and RVD. Urine and HVS samples were also collected 
for analysis, culture and sensitivity. 
  Laboratory results showed positive to MP and HIV-1 with 
a yield growth of coliforms. At her next visit, she was given 
a second degree counseling on HIV/AIDS and was asked to 
come back on a later date with her husband. The husband 
obliged and came out negative with a triple-method testing 
check (Screening a patient’s sample with 3standard HIV-kits 
of different make). His sample was further collected post 3 
and 6-months for Western-Blot method (Immuno-Confirm), 
used for HIV confirmation and he still came out negative. 
But that of his wife still came out confirmed positive for 
HIV-1. 
  On further questioning, the couple could only remember 
a case of complicated still-birth that resulted in blood 
transfusion on 15th of January, 2000. Over 8 years from the 
date of her first clinic visit. There were no observable typical 
HIV/AIDS observations/symptoms on the woman and she 
has had no standard anti retro-viral drugs within the said 
period.
3. Case report 2
  The second case involves a family of six. A couple with 
four children of ages about 6 months, 2 years, 3 years and 5 
years. Both parents are petty-traders and the family lives in 
a Sub-Urban area of the Metropolis. The youngest, a female 
presented with fever and multiple lymphadenopathy. She 
was said to be rejecting food and breast milk and showing 
signs of restlessness. She tested HIV positive to both 
screening and confirmatory. 
  In line with our hospital management policy, her entire 
family was invited and blood samples collected for both 
screening and confirmatory methods. Her mother and her 
second sibling age 3 came out confirmed positive. But her 
father and two other siblings, ages of 2 and 5 remained 
negative at post three and six months intervals from their 
very first test date.
3. Discussion
  A non published source has demonstrated a case of HIV 
seropositive of over eleven years standing with no clinical 
signs and in complete absence or non-usage of any known 
standard anti retro-viral drugs. 
  The first major peculiarity of our two cases report is the fact 
that HIV seropositive cases had remained without clinical 
signs in complete absence or non usage of any known 
standard antiretro viral drugs. Could the school of thought 
that insists on the fact that HIV kills with “know and fear” 
of the suffer be right? According to NACA[8], most cases of 
reported HIV infection in Africa, present with clinical signs 
within the first 1-2 years with most patients dying in the first 
three years if untreated, globally. 
  It has been reported that most cases of seropositive HIV 
manifest clinically, within the first 5 years and maximally 
before ten years. But, this position was said to only be 
possible in developed countries and with people on proper 
diet and highly hygienic life style. In our cases reported, the 
families are below average Nigerian families thus can not be 
said to be on proper diet and Nigeria is not yet among the 
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developed countries. The part of the country where they live 
is also not part of the high hygienic areas of Nigeria.
  The second peculiarity in our cases report is the selective 
nature of HIV infectivity within people with equal risk of 
exposure. In the first reported case, the woman has had 
active faithful sexual life with her husband. The man who 
has had nothing of economical earnings for over three years 
could only but, work along the wife’s petty-trading and 
Church orderly job. 
  Sexual life-style has been documented to be more active 
among this lower cadre of people as they usually have more 
ample time to themselves. It follows logically, that this 
couple has indeed had active sexual life in the past over 
eight years.The woman most probably may have had a CD4 
count of over 800 but, the so called micro-trauma ought to 
have occurred over the years.
  The most astonishing part is the gross disparity of infection 
in the  second family. The children were all delivered in the 
same hospital and the last child who most possibly has had 
a safer precautionary delivery, came down with the disease.
  According to Ao and colleagues[9], APOBEC3G (A3G), a 
deoxycytidine deaminase is a potent host antiviral factor 
that can restrict HIV-1 infection. The A3G is found naturally 
and its plasma level may be of clinical importance just like 
that of bcg-antigen/antibody that protects naturally against 
tuberculosis. HIV-1 synthesizes a viral infectivity factor 
(Vif) to counter A3G restriction but, it is poorly understood 
how the human cellular factors regulate the plasma level of 
A3G[10].
  The Vif is found only on HIV-1[11-13] and all of our 
cases report are those of infliction with HIV -1. Perhaps 
this is pattern that is helpful in cubing the spread of HIV 
transmission in this part of the world since HIV-2 is very 
uncommon in Nigeria. 
  It is our cock believe from our findings that A3G and Vif 
are responsible for the selective infectivity and virulence 
or its delay. Where the interplay between the A3G with 
Vif remains active with neither overwhelming the other, 
Virulence will be delayed or suppressed for a long like 
those of our of typical case mothers. Where A3G completely 
overwhelms Vif, there may be an outright sero-negative 
as has been seen in these cases reported and finally where 
Vif overwhelms A3G, sero-positive case ensues as well 
the development of  an outright virulence. The protective 
mechanism  of A3G centres on apolipoprotein B-mRNA 
editing enzyme, catalytic polypeptide-Like 3G; a DNA-
editing enzyme produced by host cells infected by certain 
retroviruses that is then incorporated into the virions. The 
cytidine deaminase activity of A3G aids its mutation of the 
minus-strand DNA formed during reverse transcription 
thus A3G particularly, blocks reverse transcription in retro 
viruses[14] An enzyme linked depletion of A3G comes with 
the activity of E3 Ligase complex that is recruited by Vif.
  Drugs targets on anti-E3 Ligase along with analogs of 
A3G could possibly put an end to the scourging effect of 
HIV/AIDS. In our final words, we support the opinion on a 
naturally, occurring substance, APOBEC3G which possibly 
confers permanent immunity against the HIV virus. We 
recommend clinical trials of the characterized APOBEC3G 
as a vaccine for non HIV infected persons of all ages and to 
people living with HIV/AIDS as a therapeutic drug.   
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